Abstract 17700: Comparison of Biodegradable Polylactide-Glycolic Acid (PLGA) Polymer Sirolimus Eluting (BuMA) Stent with Everolimus Eluting Stent for Early Neointimal Coverage: An Optical Coherence Tomography Study
Backgrounds: BuMA stent is a recently developed biodegradable stent which showed rapid endothelialization in animal studies. The aim of the study was to compare BuMA stent with everolimus eluting stent (Xience V) for in vivo neointimal coverage at 3 months by optical coherence tomography (OCT).
Method: 20 patients with single long lesion (length ≥ 20mm) were enrolled. One BuMA stent and one EES stent were implanted with short overlap (3.0-5.0 mm) in the same vessel. The patients were randomly allocated into (1) distal BuMA stent and proximal Xience V stent or (2) opposite order. OCT was performed at 3 month follow-up to evaluate the neointimal coverage.
Results: All 20 patients finished 3 month follow-up. There was no difference in diameter or length of the lesion at baseline (BuMA vs. Xience V: 2.89±0.36 vs. 2.95±0.43 mm in diameter, p=0.622, 23.5±4.32 vs. 23.7±3.89 mm in length, p=0.879). At 3 month follow-up, the degree of neointimal coverage was not different between the two groups (BuMA vs. Xience V: 95.4% vs. 94.8%, p=0.724). However, BuMA stents had larger neointimal area than Xience V stent (0.84±0.47 vs. 0.75±0.37 mm2 in area, p=0.003). No in-stent thrombosis or MACE occurred during 3 month follow-up in this cohort (Figure).
Conclusion: Both BuMA stent and Xience V stent had excellent comparable strut coverage at 3 months.
- © 2012 by American Heart Association, Inc.